Who manufactures Nexavar?
Development Timeline for Nexavar
|Jul 1, 2013||Bayer and Onyx Pharmaceuticals Announce Submission of FDA and EMA Applications for Nexavar (sorafenib) for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer|
How is sorafenib administered?
The recommended daily dose of NEXAVAR is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.
What is the cost of sorafenib?
The costs and effectiveness of sorafenib estimated by the authors were almost the same as those estimated in our study: US$ 19,149 and 0.45 QALYs per patient, compared to an estimated US$ 12,798 and 0.38 QALYs per patient in our model.
What is Nexavar 200 mg used for?
Nexavar (sorafenib) is a cancer (chemotherapeutic) medication used to treat a type of kidney cancer called advanced renal cell carcinoma. Nexavar is also used to treat liver cancer.
What is Nexavar used to treat?
NEXAVAR is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma (1.1) Advanced renal cell carcinoma (1.2) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment (1.3) ATION – 400 mg (2 tablets) orally twice daily without food.
What is the composition of the Nexavar tablets?
Nexavar tablets are supplied as round, biconvex, red film-coated tablets, debossed with the “Bayer cross” on one side and “200” on the other side, each containing sorafenib tosylate equivalent to 200 mg of sorafenib.
Is Nexavar used to treat differentiated thyroid cancer?
Differentiated Thyroid Carcinoma. Nexavar is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
What are the contraindications for Nexavar?
NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. (4) NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.